Oral Cancer Drugs

Question 1

Which oral targeted therapy drug attacks the BRAF gene mutation?

Answer 1

Dabrafenib (Tafinlar)

Question 2

Which oral targeted therapy drug attacks the EGFR gene mutation?

Answer 2

Gefitnib (Iressa)

Question 3

Which oral targeted therapy drug is is a ROSI gene drug?

Answer 3

crizotinib (Xalkori)

Question 4

Which oral targeted therapy drug is is a NTRK gene drug?

Answer 4

laratrectinib (Vitrakvi)

Question 5

Ribociclib indications

Answer 5

For the adjuvant treatment of hormone receptor (HR)-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, in combination with an aromatase inhibitor

Question 6

Ribociclib classification

Answer 6

Small Molecule Antineoplastic Cyclin-Dependent Kinase (CDK) Inhibitors

Question 7

Ribociclib Contraindications/Precautions

Answer 7

Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner; these ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption.

Question 8

Dabrafenib indication

Answer 8

malignant melanoma

Question 9

Dabrafenib considerations

Answer 9

Confirm the BRAF V600E or V600K mutation prior to starting therapy.

Question 10

Dabrafenib classification

Answer 10

kinase inhibitor that inhibits cell growth in BRAF V600 mutation-positive tumors.

Question 11

Dabrafenib Contraindications/Precautions

Answer 11

not indicated for the treatment of BRAF wild-type melanoma